Evidence map›Paper›PMID 25586507›Full record

ArticleClinical research in cardiology : official journal of the German Cardiac Society2015

Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction.

Fernando Friões, Patrícia Lourenço, Olga Laszczynska, Pedro-Bernardo Almeida, João-Tiago Guimarães, James L Januzzi, Ana Azevedo, Paulo Bettencourt

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide.Journal of cardiovascular development and disease · 2023
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Redefining biomarkers in heart failure.Heart failure reviews · 2018
    Review
  18. Circadian rhythm of blood cardiac troponin T concentration.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Fernando FriõesDepartment of Internal Medicine, São João Hospital Centre, Alameda Prof. Hernâni Monteiro, 4200-319, Porto, Portugal, fbfrioes@gmail.com.
Patrícia Lourenço
Olga Laszczynska
Pedro-Bernardo Almeida
João-Tiago Guimarães
James L Januzzi
Ana Azevedo
Paulo Bettencourt
Universidade do Porto · PTHospital de São João · PTMassachusetts General Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNatriuretic peptides and suppression of tumorigenicity 2 (ST2) represent two different physiopathological pathways. We evaluated the prognostic accuracy and complementarity of B-type natriuretic peptide (BNP) and soluble ST2 (sST2) plasma levels at discharge from a hospital admission for acute heart failure, both in patients with preserved (HFpEF) and depressed (HFrEF) systolic function. METHODS AND

resultsWe enrolled 195 consecutive patients discharged alive and followed them prospectively for 6 months. The endpoint was all-cause death or hospital readmission for heart failure. Seventy-six patients had HFpEF and 119 had HFrEF, of whom 23 (30.3%) and 43 (36.1%) reached the combined endpoint, respectively. In both HFpEF and HFrEF, having the two biomarkers into account added prognostic information, with the highest risk in patients with both biomarkers above the median in their group (approximately 40% hospitalization-free survival in both groups at 6 months). These associations translated into a significant fourfold increase in risk of the endpoint for one elevated biomarker and sevenfold for both biomarkers elevated in HFrEF, and no association for one elevated biomarker and fivefold increase in risk for both biomarkers elevated in HFpEF. Considering the reclassification of risk added to BNP by measurement of sST2, net reclassification index was 0.31 (p = 0.21) among patients with HFpEF and 0.70 (p < 0.001) among patients with HFrEF.

conclusionssST2 provides robust prognostic information in acute heart failure with HFrEF, while this pattern was less clear in HFpEF. When sST2 was measured together with BNP, it improved prognostic accuracy in both groups, more clearly in HFrEF.

Indexed as

Acute DiseaseAgedAged, 80 and overBiomarkersFemaleHeart FailureHospitalizationHumansInterleukin-1 Receptor-Like 1 ProteinMaleMiddle AgedNatriuretic Peptide, BrainPrognosisProspective StudiesReceptors, Cell SurfaceBiomarkersIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinNatriuretic Peptide, BrainReceptors, Cell Surface

Identifiers

PMID25586507
OpenAlexW2091173764

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.